Triple-negative breast cancers (TNBC), a breast cancer subtype with more aggressive biology, high rates of metastasis and potential relapse and mortality, stands out as having limited therapeutic options [2] and affects nearly 10–20% of all diagnosed breast cancers [3], mainly in younger (under forty years of age, [4]), African Americans [5], Hispanic women [6] and/or individuals with a BRCA1 gene mutation [4]. This evidence concerns the gene BRCA1 and breast carcinoma.